SAB Biotherapeutics and Big Cypress Acquisition have entered into a definitive business combination agreement. Upon closing of the proposed transaction, the combined company will operate as SAB Biotherapeutics with Big Cypress Acquisition’s Samuel Reich and Jeffrey Spragens joining the SAB board.
SAB plans to list on the Nasdaq following the closing of the transaction. The proposed transaction implies an enterprise value for SAB, on a post-merger basis, of approximately $325 million and is expected to provide the combined company with approximately $118 million of pro forma cash (assuming no redemptions from Big Cypress’ trust account).
SAB is a clinical-stage biopharmaceutical company with an immunotherapy platform that produces targeted, high potency, fully-human polyclonal antibodies at scale. Read more.
